AVROBIO logo
AVROBIO AVRO

Quarterly report 2026-Q1
added 05-07-2026

report update icon

AVROBIO Accounts Payables 2011-2026 | AVRO

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables AVROBIO

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.09 M 976 K 409 K 384 K 3.49 M 2.68 M 3.95 M 2.78 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.95 M 384 K 1.97 M

Quarterly Accounts Payables AVROBIO

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
2.55 M 1.48 M 2.8 M 6.25 M 976 K 2.64 M 4.09 M 243 K 409 K 910 K 1.07 M 591 K 384 K 1.81 M 28 K 4.04 M 3.49 M 2.97 M 2.03 M 2.7 M 2.68 M 2.68 M 2.68 M 2.68 M 3.95 M 3.95 M 3.95 M 3.95 M 2.78 M 2.78 M 2.78 M 2.78 M 527 K 527 K 527 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
6.25 M 28 K 2.31 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
1.73 M - 1.35 % $ 17.8 M chinaChina
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
32.6 M $ 16.87 -2.49 % $ 789 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
1.93 M - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
570 M - - $ 866 M chinaChina
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
4.24 M $ 7.47 -4.6 % $ 205 M israelIsrael
Athira Pharma Athira Pharma
ATHA
4.59 M - - $ 269 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
265 K - -32.59 % $ 7.61 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
9.92 M $ 1.57 -3.68 % $ 184 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
3.08 M $ 1.63 2.52 % $ 434 M britainBritain
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
3.38 M - - $ 231 M usaUSA
Advaxis Advaxis
ADXS
6.08 M - -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
1.16 M $ 3.36 -3.72 % $ 5.53 M israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
11 M $ 30.26 1.0 % $ 814 M usaUSA
Exelixis Exelixis
EXEL
29.6 M $ 50.13 -1.9 % $ 13.6 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
677 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.91 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
611 K - 1.93 % $ 17.4 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
463 K $ 0.72 -1.58 % $ 32.9 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
65.1 M $ 3.12 - $ 649 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.91 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
724 K - -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
1.28 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
6.52 M - -0.23 % $ 916 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
14.2 M $ 2.41 4.78 % $ 67.2 M usaUSA
AlloVir AlloVir
ALVR
1.28 M - 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
1.76 M - - $ 28.6 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
9.99 M $ 23.11 -3.55 % $ 299 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
12.5 M $ 21.32 -1.16 % $ 2.71 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
1.03 M - 3.16 % $ 1.9 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
4.64 M $ 9.75 5.52 % $ 279 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
750 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
1.58 M - - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
4.29 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
3.98 M - 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
1.74 M - - $ 8.42 M usaUSA